Media stories about PTC Therapeutics (NASDAQ:PTCT) have trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. PTC Therapeutics earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.3283705070205 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- PTC Therapeutics, Inc. (PTCT) stock added 11.28% off its SMA-20 – The Stocks News (press release) (thestocksnews.com)
- PTC Therapeutics, Inc. (NASDAQ:PTCT) – Hot Stock under Consideration – Nasdaq Journal (nasdaqjournal.com)
- Notable Market Movers: PTC Therapeutics, Inc., (NASDAQ: PTCT), Cardinal Health, Inc., (NYSE: CAH); – TNN (tradingnewsnow.com)
- Stock in the Analysts Spotlight: PTC Therapeutics, Inc. (PTCT) – Wall Street Morning (wallstreetmorning.com)
- Watching Stocks News Review: PTC Therapeutics, Inc., (NASDAQ: PTCT), Duke Energy Corporation, (NYSE: DUK) – Global Export Lines (press release) (globalexportlines.com)
Shares of PTC Therapeutics (NASDAQ PTCT) opened at $30.62 on Tuesday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 2.90 and a current ratio of 3.04. PTC Therapeutics has a 12-month low of $8.12 and a 12-month high of $31.25.
PTCT has been the topic of a number of research reports. JPMorgan Chase & Co. boosted their price target on PTC Therapeutics to $15.00 and gave the company a “neutral” rating in a report on Friday, November 24th. ValuEngine downgraded PTC Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 29th. Zacks Investment Research raised PTC Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a research report on Thursday, January 4th. Barclays reaffirmed a “hold” rating on shares of PTC Therapeutics in a research report on Tuesday, January 23rd. Finally, Royal Bank of Canada started coverage on PTC Therapeutics in a research report on Monday, January 29th. They issued a “sector perform” rating on the stock. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $23.57.
In other PTC Therapeutics news, CEO Stuart Walter Peltz sold 2,230 shares of the business’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $18.03, for a total transaction of $40,206.90. Following the transaction, the chief executive officer now owns 26,646 shares of the company’s stock, valued at $480,427.38. The sale was disclosed in a document filed with the SEC, which is available through this link. In the last three months, insiders have sold 2,719 shares of company stock worth $48,848. Company insiders own 8.10% of the company’s stock.
PTC Therapeutics Company Profile
PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.